Janssen
We would like to show you a description here but the site won’t allow us.
TREMFYA® - cloud.e.janssen.com
TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may …
May 21, 2019 · Rep-Provided SPRAVATO® Resources Janssen has several SPRAVATO® resources that may be helpful to you when communicating with patients or your referral …
Las ganadoras del premio Dr. Paul Jansen 2014 se encuentran en …
En abril, TIME reveló su 12° lista anual, que incluyó a los ganadores del premio Dr. Paul Jansen 2014 por investigación biomédica: las Dras. Emmanuelle Charpentier y Jennifer Doudna.
The information in this toolkit is meant to be educational to help inform your communications. Your use of these materials is not an endorsement by Johnson & Johnson of your treatment center. …
A Study to Assess the Long-Term Safety of Ustekinumab Versus …
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of …
«Янссен» объявляет о регистрации новых показаний …
Feb 27, 2020 · Пожилым пациентам, которым противопоказана трансплантация, доступно ограниченное количество опций первой линии терапии, поэтому мы рады, что с …
Tremfya - cloud.e.janssen.com
We look forward to sharing more with you about TREMFYA ® (guselkumab). In the meantime, if you have any questions, feel free to call a Janssen CarePath Care Coordinator at …
Oncologia e Hematologia│ Janssen Portugal
O cancro afeta milhões de pessoas. As nossas soluções inovadoras na Oncologia visam dar qualidade de vida aos doentes e descobrir as curas do amanhã.
OPSYNVI® (macitentan et tadalafil) devient le premier et le seul ...
OPSYNVI® (macitentan et tadalafil) devient le premier et le seul traitement d’association à doses fixes uniquotidien approuvé par Santé Canada pour les patients atteints d’hypertension …